A depot neuroleptic withdrawal study neurological effects.

Area of Science:

• Psychiatry
• Clinical Pharmacology
• Neuroscience

Background:

• Chronic schizophrenia management often involves long-term neuroleptic treatment.
• Depot neuroleptics offer an alternative administration route for antipsychotic medications.
• Understanding the efficacy and side effect profiles of different depot neuroleptics is crucial for patient care.

Purpose of the Study:

• To compare the efficacy of depot neuroleptics (fluphenazine decanoate and flupenthixol decanoate) versus placebo in preventing relapse in chronic schizophrenic outpatients.
• To evaluate and compare neurological side effects, including extrapyramidal symptoms (EPS) and tardive dyskinesia (TD), during neuroleptic therapy and withdrawal.
• To assess the relationship between TD symptoms and relapse rates.

Main Methods:

• A 6-month, double-blind, placebo-controlled withdrawal trial involving 41 chronic schizophrenic outpatients.
• Patients received either fluphenazine decanoate, flupenthixol decanoate, or placebo.
• Assessment included relapse rates, rehospitalization, occurrence of EPS (akathisia), TD, and changes in EPS scores and weight.

Main Results:

• Depot neuroleptics were significantly more effective than placebo in preventing relapse (27% vs. 62% relapse rate).
• Akathisia was significantly more frequent in the fluphenazine decanoate group (23.7%) compared to other groups.
• Six cases of tardive dyskinesia (15.8%) were observed, with no clear relation to relapse; EPS scores and weight decreased significantly during placebo treatment.

Conclusions:

• Depot neuroleptics are effective in maintaining remission and preventing relapse in chronic schizophrenia.
• Fluphenazine decanoate may be associated with a higher risk of akathisia compared to flupenthixol decanoate.
• Further research is needed to fully elucidate the long-term neurological side effect profiles of different depot neuroleptics.